Decreased proportion of peripheral blood vascular endothelial growth factor-expressing T and natural killer cells in preeclampsia

American Journal of Obstetrics and Gynecology

Volumn 203, Issue 6, 2010, Pages 567.e1-567.e8

  Molvarec, Attila ^a   Ito, Mika ^c   Shima, Tomoko ^c   Yoneda, Satoshi ^c   Toldi, Gergely ^b   Stenczer, Balázs ^a   Vásárhelyi, Barna ^b   Rigó Jr , János ^a   Saito, Shigeru ^c  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Inflammation; Lymphocyte; Preeclampsia; Pregnancy; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN; BIOLOGICAL MARKER; VASCULOTROPIN A;

ADULT; ARTICLE; BLOOD; BODY MASS; CASE CONTROL STUDY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; CYTOTOXIC T LYMPHOCYTE; DIASTOLIC BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INTERMETHOD COMPARISON; LYMPHOCYTE SUBPOPULATION; NATURAL KILLER CELL; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE; COMPARATIVE STUDY; NATURAL KILLER T CELL; PREGNANCY OUTCOME; REFERENCE VALUE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; NATURAL KILLER T-CELLS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 79952118096     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2010.07.019     Document Type: Article

References (40)

1. Duckitt K, Harrington D. Risk factors for preeclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005;330: 565.
2. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol1999;180: 499-506. (Pubitemid 29093892)
3. Saito S, Shiozaki A, Nakashima A, Sakai M, Sasaki Y. The role of the immune system in preeclampsia. Mol Aspects Med 2007;28: 192-209. (Pubitemid 46843191)
4. Saito S, Sakai M. Th1/Th2 balance in preeclampsia. J Reprod Immunol 2003;59: 161-73. (Pubitemid 36945234)
5. Maharaj AS, D'Amore PA. Roles for VEGF in the adult. Microvasc Res 2007;74: 100-13. (Pubitemid 350051021)
6. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006;312: 549-60. (Pubitemid 43290332)
7. Sasaki Y, Darmochwal-Kolarz D, Suzuki D, et al. Proportion of peripheral blood and decidual CD4(+) CD25(bright) regulatory T cells in preeclampsia. Clin Exp Immunol 2007;149: 139-45. (Pubitemid 46897107)
8. Darmochwal-Kolarz D, Rolinski J, Leszczynska-Goarzelak B, Oleszczuk J. The expressions of intracellular cytokines in the lymphocytes of preeclamptic patients. Am J Reprod Immunol 2002;48: 381-6. (Pubitemid 35469289)
9. Freeman MR, Schneck FX, Gagnon ML, et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 1995; 55: 4140-5.
10. Hanna J, Goldman-Wohl D, Hamani Y, et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med 2006;12: 1065-74. (Pubitemid 44353388)
11. Kopcow HD, Karumanchi SA. Angiogenic factors and natural killer (NK) cells in the pathogenesis of preeclampsia. J Reprod Immunol 2007;76: 23-9. (Pubitemid 350100881)
12. Matsuyama W, Kubota R, Hashiguchi T, et al. Purified protein derivative of tuberculin upregulates the expression of vascular endothelial growth factor in T lymphocytes in vitro. Immunology 2002;106: 96-101. (Pubitemid 34437882)
13. Joubert K. Standards of the body mass and body length of birth in Hungary on the basis of the 1990-1996 nation-wide liveborn data. Magy Noorv L 2000;63: 155-63.
14. He H, Venema VJ, Gu X, Venema RC, Marrero MB, Caldwell RB. Vascular endothelial growth factor signals endothelial cell productionof nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem 1999; 274: 25130-5.
15. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renaldiseases. J Clin Invest 2003;111: 707-16. (Pubitemid 36278589)
16. Kitamoto Y, Takeya M, Tokunaga H, Tomita K. Glomerular endothelial cells are maintained by vascular endothelial growth factor in the adult kidney. Tohoku J Exp Med 2001;195: 43-54. (Pubitemid 34036885)
17. Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003;278: 12605-8. (Pubitemid 36800018)
18. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-34. (Pubitemid 36910021)
19. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and evacizumab. N Engl J Med 2006;354: 980-2.
20. Rajakumar A, Michael HM, Rajakumar PA, et al. Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta 2005;26: 563-73. (Pubitemid 40916309)
21. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111: 649-58. (Pubitemid 36278583)
22. Nagamatsu T, Fujii T, Kusumi M, et al. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 2004;145: 4838-45. (Pubitemid 39551100)
23. Nevo O, Soleymanlou N, Wu Y, et al. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regulatory Integrative Comp Physiol 2006;291: R1085-93. (Pubitemid 44498450)
24. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350: 672-83. (Pubitemid 38364626)
25. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005; 308: 1592-4. (Pubitemid 40807500)
26. Mor F, Quintana FJ, Cohen IR. Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization. J Immunol 2004;172: 4618-23. (Pubitemid 38375280)
27. Ness RB, Roberts JM. Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. Am J Obstet Gynecol 1996;175: 1365-70. (Pubitemid 26399006)
28. Papazoglou D, Galazios G, Koukourakis MI, et al. Vascular endothelial growth factor gene polymorphisms and pre-eclampsia. Mol Hum Reprod 2004;10: 321-4. (Pubitemid 38714362)
29. Banyasz I, Szabo S, Bokodi G, et al. Genetic polymorphisms of vascular endothelial growth factor in severe pre-eclampsia. Mol Hum Reprod 2006;12: 233-6. (Pubitemid 43779074)
30. Shim JY, Jun JK, Jung BK, et al. Vascular endothelial growth factor gene μ936 C/T polymorphism is associated with preeclampsia in Korean women. Am J Obstet Gynecol 2007; 197: 271e1-4.
31. Nagy B, Savli H, Molvarec A, et al. Vascular endothelial growth factor (VEGF) polymorphisms in HELLP syndrome patients determined by quantitative real-time PCR and melt ing curve analyses. Clin Chim Acta 2008; 389: 126-31.
32. Sandrim VC, Palei AC, Cavalli RC, et al. Vascular endothelial growth factor genotypes and haplotypes are associated with preeclampsiabut not with gestational hypertension. Mol Hum Reprod 2009;15: 115-20.
33. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355: 992-1005. (Pubitemid 44343543)
34. Nadar SK, Karalis I, Al Yemeni E, Blann AD, Lip GY. Plasma markers of angiogenesis in pregnancy induced hypertension. Thromb Haemost 2005;94: 1071-6. (Pubitemid 41645951)
35. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12: 642-9. (Pubitemid 43865232)
36. Molvarec A, Jermendy A, Nagy B, et al. Association between tumor necrosis factor (TNF)-alpha G-308A gene polymorphism and preeclampsia complicated by severe fetal growth restriction. Clin Chim Acta 2008;392: 52-7.
37. Molvarec A, Rigo J Jr, Lazar L, et al. Increased serum heat-shock protein 70 levels reflect systemic inflammation, oxidative stress and hepatocellular injury in preeclampsia. Cell Stress Chaperones 2009;14: 151-9.
38. Rosta K, Molvarec A, Enzsoly A, et al. Association of extracellular superoxide dismutase (SOD3) Ala40Thr gene polymorphism with pre-eclampsia complicated by severe fetal growth restriction. Eur J Obstet Gynecol Reprod Biol 2009;142: 134-8.
39. Molvarec A, Rigo J Jr, Boze T, et al. Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia. Thromb Haemost 2009;101: 305-11.
40. Nagy B, Varkonyi T, Molvarec A, et al. Leptin gene (TTTC)(n) microsatellite polymorphism in pre-eclampsia and HELLP syndrome. Clin Chem Lab Med 2009;47: 1033-7.